Category: Press Release

Explore all our news . .

Recent Posts

LyondellBasell completes sale of select European strategic assessment assets

Transaction with AEQUITA advances company’s portfolio realignment ROTTERDAM, Netherlands, May 01, 2026 (GLOBE NEWSWIRE) — LyondellBasell (NYSE: LYB) today announced that it has successfully completed the sale of select European olefins and polyolefins assets, and the associated business and corporate functions, to AEQUITA as a key milestone in the company’s

Nyxoah to Participate in the Bank of America 2026 Healthcare Conference

Nyxoah to Participate in the Bank of America 2026 Healthcare Conference Mont-Saint-Guibert, Belgium – April 30, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive

Driving Elegance Together — LEPAS Global Partner Conference Successfully Concludes

LEPAS presents its vision of “Driving Elegance Together,” blending refined design, intelligent technology, and an elevated lifestyle experience.[/caption] WUHU, China, April 29, 2026 (GLOBE NEWSWIRE) — From April 26 to 28, 2026, LEPAS, the NEV brand under Chery Group, hosted its first Global Partner Conference in Wuhu under the theme

VertiGIS Acquires 1Spatial to Expand its Product Portfolio and Global Reach

Take-private deal, valued at £87 million, to help VertiGIS power the next generation of intelligent, insight-driven geospatial networks London, UK. 30 April 2026 – VertiGIS, a global leader in geospatial solutions for utilities, governments and commercial enterprises, today announces it has closed its acquisition of 1Spatial, a longstanding VertiGIS partner

Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026

Nyxoah to Release First Quarter 2026 Financial Results on May 12, 2026 Mont-Saint-Guibert, Belgium – April 28, 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company